Highlights:
- Britain signs deals of 9 crore doses of Coronavirus vaccine
- 3 crore of this is of BioNTech/Pfizer vaccine
- 6 crore is of Valneva vaccine
- Oxford’s potential vaccine is already in large-scale Phase III of human trials
Britain has signed deals in which it will procure 90 million or 9 crore doses of 2 possible COVID-19 vaccines from BioNTech and Pfizer alliance as well as the French group Valneva.
A leading international news agency reports that Britain has secured 30 million or 3 crore doses of the experimental BioNTech/ Pfizer vaccine and also made a deal in principle for 60 million or 6 crore doses of the Valneva vaccine with an option of procuring additional 40 million or 4 crore doses if it is proven to be effective, suitable and safe.
As of now, BioNTech is developing a potential vaccine for the novel Coronavirus in collaboration with the pharmaceutical giant of the United States of America, Pfizer.
Currently, more than 150 potential COVID-19 vaccines are being developed and/ or tested all around the globe to try to stop the pandemic right in its track.
Earlier, Moderna, a US-based Biotech company said that it is going to start the final stage human trials for its COVID-19 vaccine from the 27th of July. The company added that its vaccine showed promising results in the earlier stages of testing. As many as 30,000 Americans are expected to take part in the trails for the vaccine.
The Oxford’s potential vaccine for the novel Coronavirus has been licensed to AstraZeneca which is already in the large-scale Phase III of human trials to assess if the vaccine can protect people against the novel Coronavirus.
Researchers in the United States of America, earlier, reported that the experimental vaccine of Moderna Inc has shown that it is safe and even provoked the immune responses in all of the 45 healthy volunteers in an ongoing early-stage study.
